Romosozumab and antiresorptive treatment: the importance of treatment sequence

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Felicia Cosman, Columbia University
  • ,
  • David L. Kendler, University of British Columbia
  • ,
  • Bente L. Langdahl
  • Benjamin Z. Leder, Harvard University
  • ,
  • E. Michael Lewiecki, New Mexico Clinical Research & Osteoporosis Center
  • ,
  • Akimitsu Miyauchi, Miyauchi Medical Center
  • ,
  • Maria Rojeski, Amgen Incorporated
  • ,
  • Michele McDermott, Amgen Incorporated
  • ,
  • Mary K. Oates, Amgen Incorporated
  • ,
  • Cassandra E. Milmont, Amgen Incorporated
  • ,
  • Cesar Libanati, UCB S.A.
  • ,
  • Serge Ferrari, University of Geneva

Summary: To evaluate whether treatment sequence affects romosozumab response, this analysis reviewed studies where romosozumab was administered before or following an antiresorptive (alendronate or denosumab). Initial treatment with romosozumab followed by an antiresorptive resulted in larger increases in bone mineral density of both hip and spine compared with the reverse sequence. Introduction: Teriparatide followed by an antiresorptive increases bone mineral density (BMD) more than using an antiresorptive first. To evaluate whether treatment sequence affects romosozumab response, we reviewed randomized clinical trials where romosozumab was administered before (ARCH, FRAME) or following (STRUCTURE, Phase 2 extension) an antiresorptive (alendronate or denosumab, respectively). Methods: We evaluated BMD percentage change for total hip (TH) and lumbar spine (LS) and response rates (BMD gains ≥ 3% and ≥ 6%) at years 1 and 2 (except STRUCTURE with only 1-year data available). Results: With 1-year romosozumab initial therapy in ARCH and FRAME, TH BMD increased 6.2% and 6.0%, and LS BMD increased 13.7% and 13.1%, respectively. When romosozumab was administered for 1 year after alendronate (STRUCTURE) or denosumab (Phase 2 extension), TH BMD increased 2.9% and 0.9%, respectively, and LS BMD increased 9.8% and 5.3%, respectively. Over 2 years, TH and LS BMD increased 7.1% and 15.2% with romosozumab/alendronate, 8.5% and 16.6% with romosozumab/denosumab, and 3.8% and 11.5% with denosumab/romosozumab, respectively. A greater proportion of patients achieved BMD gains ≥ 6% when romosozumab was used first, particularly for TH, versus the reverse sequence (69% after romosozumab/denosumab; 15% after denosumab/romosozumab). Conclusion: In this study, larger mean BMD increases and greater BMD responder rates were achieved when romosozumab was used before, versus after, an antiresorptive agent. Since BMD on treatment is a strong surrogate for bone strength and fracture risk, this analysis supports the thesis that initial treatment with romosozumab followed by an antiresorptive will result in greater efficacy versus the reverse sequence.

Original languageEnglish
JournalOsteoporosis International
Pages (from-to)1243-1256
Number of pages14
Publication statusPublished - Jun 2022

Bibliographical note

Publisher Copyright:
© 2022, The Author(s).

    Research areas

  • Anabolic, Antiresorptive, Romosozumab, Teriparatide, Treatment sequence

See relations at Aarhus University Citationformats

ID: 269390496